These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2344861)

  • 41. Pharmacokinetics of pentopril in the elderly.
    Rakhit A; Kochak GM; Tipnis V; Radensky P; Hurley ME; Williams R
    Br J Clin Pharmacol; 1987 Sep; 24(3):351-7. PubMed ID: 2822067
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of a new benazepril hydrochloride chewable tablet and evaluation of its bioequivalence for treatment of heart failure in dogs.
    Qian M; Chen T; Zhou D; Zhang Z; Zhang Q; Tang S; Xiao X
    J Vet Pharmacol Ther; 2016 Feb; 39(1):98-101. PubMed ID: 26228576
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical pharmacokinetics of the newer ACE inhibitors. A review.
    Kelly JG; O'Malley K
    Clin Pharmacokinet; 1990 Sep; 19(3):177-96. PubMed ID: 2203579
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Renal actions of the new angiotensin-converting enzyme inhibitor benazepril hydrochloride.
    Levens NR
    Arch Int Pharmacodyn Ther; 1988; 296():131-43. PubMed ID: 2853611
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interaction between furosemide and the converting enzyme inhibitor benazepril in healthy volunteers.
    De Lepeleire I; Van Hecken A; Verbesselt R; Kaiser G; Barner A; Holmes I; De Schepper PJ
    Eur J Clin Pharmacol; 1988; 34(5):465-8. PubMed ID: 3203706
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics and pharmacodynamics of temocapril during repeated dosing in elderly hypertensive patients.
    Arakawa M; Sasaki M; Ohmori M; Harada K; Fujimura A
    Eur J Clin Pharmacol; 2001; 56(11):775-9. PubMed ID: 11294366
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics and pharmacodynamics of quinaprilat after low dose quinapril in patients with terminal renal failure.
    Wolter K; Fritschka E
    Eur J Clin Pharmacol; 1993; 44 Suppl 1():S53-6. PubMed ID: 8387427
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women.
    Peck RW; Seaber EJ; Dixon RM; Layton GR; Weatherley BC; Jackson SH; Rolan PE; Posner J
    Clin Pharmacol Ther; 1998 Mar; 63(3):342-53. PubMed ID: 9542478
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of aging on the pharmacokinetics and pharmacodynamics of prazosin.
    Andros E; Detmar-Hanna D; Suteparuk S; Gal J; Gerber JG
    Eur J Clin Pharmacol; 1996; 50(1-2):41-6. PubMed ID: 8739810
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term effects of benazepril on ambulatory blood pressure, left ventricular mass, diastolic filling and aortic flow in essential hypertension.
    Porcellati C; Verdecchia P; Schillaci G; Boldrini F; Motolese M
    Int J Clin Pharmacol Ther Toxicol; 1991 May; 29(5):187-97. PubMed ID: 1830037
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Unmasking of the hypotensive effect of nifedipine in normotensives by addition of the angiotensin converting enzyme inhibitor benazepril.
    Jakobsen J; Glaus L; Graf P; Degen P; Maurice NP; Bellet M; Ménard J
    J Hypertens; 1992 Sep; 10(9):1045-51. PubMed ID: 1328364
    [TBL] [Abstract][Full Text] [Related]  

  • 52. General pharmacology of the novel angiotensin converting enzyme inhibitor benazepril hydrochloride. Effects on cardiovascular, visceral and renal functions and on hemodynamics.
    Yamamoto S; Takemori E; Hasegawa Y; Kuroda K; Nakao K; Inukai T; Sakonjyo H; Nishimura T; Nishimori T
    Arzneimittelforschung; 1991 Sep; 41(9):913-23. PubMed ID: 1796919
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An open-label, randomized, controlled, 4-week comparative clinical trial of barnidipine hydrochloride, a calcium-channel blocker, and benazepril, an angiotensin-converting enzyme inhibitor, in Chinese patients with renal parenchymal hypertension.
    Chen X; Zheng F; Chen P; Tang L; Wei R; Yu Y; Su Y; Kikkawa T; Yamamoto M
    J Int Med Res; 2006; 34(2):121-8. PubMed ID: 16749407
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Arterial and endocrine effects of a combination of an angiotensin converting enzyme inhibitor and a vasodilator in normotensive healthy volunteers.
    Brunel P; Guyene TT; Howald H; Ménard J
    J Cardiovasc Pharmacol; 1991 Aug; 18(2):175-81. PubMed ID: 1717776
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacodynamic evaluation of 4 angiotensin-converting enzyme inhibitors in healthy adult horses.
    Afonso T; Giguère S; Rapoport G; Berghaus LJ; Barton MH; Coleman AE
    J Vet Intern Med; 2013; 27(5):1185-92. PubMed ID: 23952255
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients.
    Stangier J; Su CA; Roth W
    J Int Med Res; 2000; 28(4):149-67. PubMed ID: 11014323
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.
    Hübner R; Högemann AM; Sunzel M; Riddell JG
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S19-25. PubMed ID: 9331000
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase on the vasopressor response to exogenous angiotensin I and angiotensin II challenges in healthy volunteers.
    Rousso P; Buclin T; Nussberger J; Brunner-Ferber F; Brunner HR; Biollaz J
    J Cardiovasc Pharmacol; 1998 Mar; 31(3):408-17. PubMed ID: 9514186
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine.
    Robertson DR; Waller DG; Renwick AG; George CF
    Br J Clin Pharmacol; 1988 Mar; 25(3):297-305. PubMed ID: 3358895
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of renal function on the pharmacokinetics and pharmacodynamics of trandolapril.
    Bevan EG; McInnes GT; Aldigier JC; Conte JJ; Grunfeld JP; Harper SJ; Meyer BH; Pauly N; Wilkinson R
    Br J Clin Pharmacol; 1993 Feb; 35(2):128-35. PubMed ID: 8443030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.